Advanced search
Publication Cover
Journal of Addictive Diseases Latest Articles
Submit an article Journal homepage
10
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Characteristics of mHealth therapy app engagement by young adults with OUD

Jennifer Stidham, BAMaryland Treatment Centers, Baltimore, MD, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0007-7818-4865View further author information
ORCID Icon,
Chinedu Jon-Emefieh, BAMaryland Treatment Centers, Baltimore, MD, USAORCID Iconhttps://orcid.org/0009-0005-8041-0847View further author information
ORCID Icon,
Jennifer Carrano, PhDMaryland Treatment Centers, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0003-3332-088XView further author information
ORCID Icon,
Kevin Wenzel, PhDMaryland Treatment Centers, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0002-6299-7569View further author information
ORCID Icon &
Marc Fishman, MDMaryland Treatment Centers, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0001-6764-6410View further author information
ORCID Icon
Published online: 24 Jun 2024

References

  • Bolívar HA, Klemperer EM, Coleman SR, DeSarno M, Skelly JM, Higgins ST. Contingency management for patients receiving medication for opioid usedisorder: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(10):1092–102. doi:10.1001/jamapsychiatry.2021.1969.
  • Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622–e1920622. doi:10.1001/jamanetworkopen.2019.20622.
  • Mintz CM, Presnall NJ, Sahrmann JM, Borodovsky JT, Glaser PE, Bierut LJ, Grucza RA. Age disparities in six-month treatment retention for opioid use disorder. Drug Alcohol Depend. 2020;216:108312. doi:10.1016/j.drugalcdep.2020.108312.
  • Fishman M, Wenzel K, Scodes J, Pavlicova M, Campbell ANC, Rotrosen J, Nunes E. Examination of correlates of OUD outcomes in young adults: secondary analysis from the XBOT trial. Am J Addict. 2021;30(5):433–44. doi:10.1111/ajad.13176.
  • Smyth BP, Barry J, Keenan E, Ducray K. Lapse and relapse following inpatient treatment of opiate dependence. Irish Med J. 2010;103(6):176–9.
  • Anderson M. 2015. Technology device ownership: 2015. Washington: Pew Research Center.
  • Leech T, Dorstyn D, Taylor A, Li W. Mental health apps for adolescents and young adults: a systematic review of randomised controlled trials. Child Youth Serv Rev. 2021;127:106073. doi:10.1016/j.childyouth.2021.106073.
  • Masson CL, Chen IQ, Levine JA, Shopshire MS, Sorensen JL. Health-related internet use among opioid treatment patients. Addict Behav Rep. 2019;9:100157. doi:10.1016/j.abrep.2018.100157.
  • Pear Therapeutics, Inc. 2020. reSET (Version 1.19) [Mobile app]. App Store. https://apps.apple.com/us/app/pear-reset/id1096230845.
  • Maricich YA, Nunes E, Campbell A, Botbyl J, Luderer H. Safety and efficacy of a digital therapeutic for substance use disorder: secondary analysis of data from a NIDA clinical trials network study. Subst Abus. 2022;43(1):937–42. doi:10.1080/08897077.2022.2060425.
  • Maricich YA, Xiong X, Gerwien R, Kuo A, Velez F, Imbert B, Boyer K, Luderer HF, Braun S, Williams K. Real-world evidence for a prescription digital therapeutic to treat opioid use disorder. Curr Med Res Opin. 2021;37(2):175–83. doi:10.1080/03007995.2020.1846023.
  • Rozycki SC, Xiong X, Walter P, Wright J, Luderer HF, Braun S, Maricich YA, Purvis J. Outcomes from engagement and use of a prescription digital therapeutic to treat opioid use disorder: a real-world pilot study. CNS Spectr. 2022;27(2):237–8. doi:10.1017/S1092852922000396.
  • Kawasaki S, Mills-Huffnagle S, Aydinoglo N, Maxin H, Nunes E. Patient-and provider-reported experiences of a mobile novel digital therapeutic in people with opioid use disorder (reSET-O): feasibility and acceptability study. JMIR Form Res. 2022;6(3):e33073. doi:10.2196/33073.
  • Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13. doi:10.1046/j.1525-1497.2001.016009606.x.
  • Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7. doi:10.1001/archinte.166.10.1092.
  • Center for Disease Control and Prevention. 2021. Drug overdose deaths in the U.S. Top 100,000 ­annually. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm.
  • Nunes E, Rotrosen J, Weiss R. Optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD). 2020 [accessed 2023 March 12] https://clinicaltrials.gov/ct2/show/NCT04464980?term=RDD&cond=Opioid%2BUse%2BDisorder&draw=2&rank=1.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.